Financial Performance - The company reported a revenue of RMB 712.9 million for the year ended December 31, 2025, representing a year-on-year growth of 15.8%[4]. - Gross profit increased to RMB 486.1 million, with a gross margin of 68.2%[4][12]. - The company reported a segment loss of RMB 215,142 thousand for the total operations, with the transcatheter valve therapy segment contributing a loss of RMB 215,517 thousand[29]. - Total revenue for the year ended December 31, 2025, reached RMB 712,870 thousand, an increase from RMB 615,483 thousand in 2024, representing a growth of approximately 15.9%[29]. - The net financial (cost) income for 2025 was a loss of RMB 3,929 thousand, a decline from a net income of RMB 17,744 thousand in 2024[39]. - The basic loss per share for the year ended December 31, 2025, was RMB (0.31), compared to RMB (0.34) for the year ended December 31, 2024, reflecting a slight improvement in loss per share[43]. - The company did not declare or pay any dividends for the year ended December 31, 2025, consistent with 2024[45]. - The company reported a pre-tax loss of RMB (202,599) thousand for 2025, an improvement from a loss of RMB (221,601) thousand in 2024[42]. - The net assets decreased to RMB 1,858.09 million as of December 31, 2025, from RMB 2,044.60 million in 2024[19]. Expenses and Cost Management - Sales and distribution expenses decreased by 2.3% to RMB 320.8 million, while administrative expenses fell by 16.6% to RMB 126.0 million[4]. - Total expenses for sales costs, sales and distribution expenses, administrative expenses, and R&D expenses amounted to RMB 928,012 thousand in 2025, an increase from RMB 864,722 thousand in 2024, representing a growth of approximately 7.3%[36]. - R&D service expenses increased significantly to RMB 104,806 thousand in 2025 from RMB 42,498 thousand in 2024, indicating a growth of approximately 147.5%[36]. - The sales and distribution expenses totaled RMB 320,813 thousand, highlighting the significant investment in market outreach and customer engagement[29]. - Administrative expenses decreased by 15.3% year-on-year to RMB 101.9 million, with the administrative expense ratio declining by 11.1 percentage points to 35.1%[13]. - The sales and distribution, administrative, and R&D expense ratios improved, decreasing by 3.5, 3.2, and 4.4 percentage points to 23.4%, 4.8%, and 9.8% respectively[15]. Research and Development - Research and development expenses rose by 25.0% to RMB 254.4 million, reflecting the company's commitment to innovation[4]. - The total R&D expenditure for the year was RMB 254,361 thousand, reflecting the company's commitment to innovation and development in medical devices[29]. - The internal R&D team consists of 152 employees focused on transcatheter valve therapy products and neurointerventional product development as of December 31, 2025[102]. - The company has developed next-generation products based on clinical feedback to optimize existing product performance and is actively advancing related iterative product development and registration[98]. - The company is actively involved in the research and development of innovative technologies for treating intracranial vascular diseases[162]. Product Development and Innovation - The company achieved a significant increase in segment profit for the neurointervention business, which grew by 86.6% to RMB 97.2 million[4][6]. - TAVR-related product sales reached RMB 290.1 million, up 11.6% year-on-year, driven by the successful launch of the TaurusMax® system[5]. - Neurointervention product sales increased by 18.9% to RMB 422.8 million, supported by strong performance of core products[5]. - The company has established a separate reporting segment for its cutting-edge technology business, which focuses on innovative solutions for heart valve diseases[28]. - The company is engaged in the development of medical devices for neurovascular diseases, with a focus on minimally invasive treatments[162]. - The company is exploring market expansion opportunities in the cardiovascular intervention sector, particularly through minimally invasive techniques[168]. Regulatory Approvals and Market Expansion - The TaurusTrio® TAV system received regulatory approval, marking a significant milestone in the company's product offerings[8]. - The DCwire® microguidewire received FDA approval in March 2026, marking a significant milestone for the company's global expansion strategy[16]. - The YonFlow® flow-directed stent received regulatory approval in April 2025, leading to its first commercial implant in June 2025, contributing significant incremental revenue[110]. - The registration application for the NRcoil® detachable coil was approved by the National Medical Products Administration in August 2023, offering a new option for embolization procedures[88]. - The company has established strong relationships with global leaders in transcatheter valve therapy and neurointerventional fields, enhancing its R&D capabilities[99]. Strategic Focus and Future Outlook - The group aims to maintain its leadership position in the Chinese TAVR market and expand its international presence in structural heart and neurovascular intervention therapies by 2030[112]. - The group plans to continue advancing the registration of the TaurusTrio® TAV system and the GeminiOne® TEER system, enhancing its product portfolio to meet unmet clinical needs[112]. - The neurointervention business is expected to enter the initial phase of global expansion by 2026, with plans for overseas regulatory registration and market access initiatives[114]. - The group will explore suitable global financing opportunities to support the development of cutting-edge treatment solutions and expand the accessibility of advanced technologies[113]. - The company is committed to ongoing research and development of new products and technologies in the field of interventional cardiology[168]. Corporate Governance and Compliance - The financial statements are prepared in accordance with the International Financial Reporting Standards, ensuring compliance and transparency in financial reporting[21]. - The audit committee has reviewed the consolidated financial statements for the reporting period and found them compliant with applicable accounting standards and regulations[153]. - The company has adopted a standard code for securities trading for directors and senior management, confirming compliance for the reporting period[151]. - The company is committed to adhering to the corporate governance code as outlined in the listing rules[160].
沛嘉医疗(09996) - 2025 - 年度业绩